Collectively, these results show that targeting CD38 by preventing its expression in the TME, or by inhibiting its enzymatic activity at the time of tumor cell implantation or after tumor establishment, attenuates B16F10 melanoma outgrowth. Here, CD38 is linked to neoplasm.